Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02728440
Other study ID # FB03232016
Secondary ID
Status Completed
Phase N/A
First received March 27, 2016
Last updated April 11, 2016
Start date May 2010
Est. completion date December 2012

Study information

Verified date March 2016
Source Gulhane School of Medicine
Contact n/a
Is FDA regulated No
Health authority Turkey: Ethics Committee
Study type Observational

Clinical Trial Summary

Effects of gonadotrophin replacement therapy Lipid Profile and Oxidative Stress Parameters of Patients with Idiopathic Hypogonadotropic Hypogonadism


Description:

30 male patients diagnosed with IHH and a control group of 20 healthy cases with similar age and BMI were included in the study. The levels of advanced oxidation protein products (AOPP), thiol, malondialdehyde (MDA), nitric oxide (NO) and 8-hydroxydeoxyguanosine (8-OHdG) and the levels of triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-K), low density lipoprotein (LDL-K), Apolipoprotein A1 (ApoA1) and Apolipoprotein B100 (ApoB100) were measured before and after gonadotrophin therapy.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 22 Years to 35 Years
Eligibility Inclusion Criteria:

Serum testosterone concentration < 300ng/dL Absence of a pituitary or hypothalamic mass lesions, Presence of gonadotropin response to GnRH, -

Exclusion Criteria:

diabetes mellitus, arterial hypertension other hormone deficiencies

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
human chorionic gonadotropin, human menopausal gonadotropin
drug for the treatment of male hypogonadism

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Gulhane School of Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary oxidative stress after hCG and HMG treatment 2010-2012 No
Primary HDL levels after hCG treatment 2010-2012 No
Primary total cholesterole levels after hCG treatment 2010-2012 No
See also
  Status Clinical Trial Phase
Terminated NCT01165619 - Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders N/A
Completed NCT01914172 - Health Needs of Patients With Kallmann Syndrome N/A
Completed NCT02042638 - The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism N/A
Active, not recruiting NCT02310074 - Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Phase 4
Completed NCT01758094 - Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism N/A
Completed NCT01601327 - Effects of Medications in Patients With Hypogonadism Phase 4
Completed NCT00493961 - Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism Phase 1
Recruiting NCT05569577 - An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients N/A